ベンリスタ(ベリムマブ)の世界市場:医薬品インサイト・市場予測

◆英語タイトル:Benlysta (belimumab) - Drug Insight and Market Forecast - 2030
◆商品コード:DELV20JU232
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(232名様閲覧)USD2,750 ⇒換算¥291,500見積依頼/購入/質問フォーム
Three UserUSD4,125 ⇒換算¥437,250見積依頼/購入/質問フォーム
Site LicenseUSD5,500 ⇒換算¥583,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

“Benlysta (belimumab) – Drug Insight and Market Forecast – 2030” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Benlysta (belimumab) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Scope of the report
The report provides insights into:

A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
Elaborated details on regulatory milestones and other development activities have been provided in this report.
The report also highlights the drug marketed details across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around Benlysta (belimumab) .
The report contains historical and forecasted sales for Benlysta (belimumab) till 2030.
Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
The report also features the SWOT analysis with analyst insights and key findings of Benlysta (belimumab) .
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Benlysta (belimumab) Analytical Perspective by DelveInsight

In-depth Benlysta (belimumab) Market Assessment
This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Benlysta (belimumab) Clinical Assessment
The report provides the clinical trials information of Benlysta (belimumab) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
In the coming years, the market scenario for Benlysta (belimumab) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Benlysta (belimumab) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Other approved products for the disease are giving market competition to Benlysta (belimumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Benlysta (belimumab) .
Our in-depth analysis of the sales data of Benlysta (belimumab) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Benlysta (belimumab) in the market.
Key Questions
What is the prescribed dosage and strengths of Benlysta (belimumab) are available in the market?
What are the common adverse reactions or side effects of Benlysta (belimumab) ?
What is the product type, route of administration and mechanism of action of Benlysta (belimumab) ?
What are the chemical specifications of Benlysta (belimumab) ?
How are the clinical trials diversified on the basis of the trial status?
What is the history of Benlysta (belimumab) , and what is its future?
What are the marketed details of Benlysta (belimumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
How many patents have been granted to Benlysta (belimumab) and when these patents will get expire?
What are the pros (benefits) and cons (disadvantages) of Benlysta (belimumab) ?
In which countries Benlysta (belimumab) got approval and when it gets launched?
What are the clinical trials are currently ongoing for Benlysta (belimumab) ?
How the safety and efficacy results determined the approval of Benlysta (belimumab) ?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Benlysta (belimumab) development?
What are the key designations that have been granted to Benlysta (belimumab) ?
What is the historical and forecasted market scenario of Benlysta (belimumab) ?
How is the market trend of Benlysta (belimumab) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
What are the other approved products available and how these are giving competition to Benlysta (belimumab) ?
Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

【レポートの目次】

1. Product Overview

1.1. Indication

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4.1 Dosage Forms and Strengths

1.4. Route of Synthesis

1.5. Pharmacology

1.4.2 Pharmacodynamics

1.4.3 Pharmacokinetics

1.6. Adverse Reactions

1.7. Product Snapshot

1.8. Development Milestones of Benlysta (belimumab)

1.9. Marketed Details

1.4.4 United States

1.4.5 Europe

1.4.6 Japan

1.10. Patent Details

2. SWOT Analysis

2.1. Analyst Views

3. Regulatory Milestones

3.1. Approvals

3.2. Research and Development

3.3. Clinical Trials Information

3.4. Safety and Efficacy

3.5. Product Developmental Activities

4. Market Assessment

4.1. 7MM Market Analysis

4.2. United States

4.3. Europe

4.4. Japan

4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

7.1. Report Purchase Options

Table 1: Benlysta (belimumab) , Description

Table 2: Benlysta (belimumab) , Trial Diversification

Table 3: Benlysta (belimumab) , Marketed Details United States

Table 4: Benlysta (belimumab) , Marketed Details Europe

Table 5: Benlysta (belimumab) , Marketed Details Japan

Table 6: Patent Details: Benlysta (belimumab)

Table 7: Benlysta (belimumab) , Clinical Trial Description, 2020

Table 8: Safety and Efficacy Results for Benlysta (belimumab)

Table 9: Benlysta (belimumab) , 7MM Market Size from 2017 to 2030 (in Million USD)

Table 10: Benlysta (belimumab) , US Market Size from 2017 to 2030 (in Million USD)

Table 11: Benlysta (belimumab) , EU Market Size from 2017 to 2030 (in Million USD)

Table 12: Benlysta (belimumab) , EU5 Market Size from 2017 to 2030 (in Millions USD)

Table 13: Benlysta (belimumab) , Japan Market Size from 2017 to 2030 (in Million USD)

Table 14: Market Competitors

Table 15: Emerging Therapies



List of Figures:

Figure 1: The Development Timeline of Benlysta (belimumab)

Figure 2: Patent Details, Benlysta (belimumab)

Figure 3: Benlysta (belimumab) , 7MM Market Size from 2017 to 2030 (in Million USD)

Figure 4: Benlysta (belimumab) , US Market Size from 2017 to 2030 (in Millions USD)

Figure 5: Benlysta (belimumab) , EU Market Size from 2017 to 2030 (in Millions USD)

Figure 6: Benlysta (belimumab) , EU5 Market Size from 2017 to 2030 (in Millions USD)

Figure 7: Benlysta (belimumab) , Japan Market Size from 2017 to 2030 (in Millions USD)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ベンリスタ(ベリムマブ)の世界市場:医薬品インサイト・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆